Study of CXCR5 Modified EGFR Targeted CAR-T Cells for Advanced NSCLC

EARLY_PHASE1RecruitingINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

September 1, 2019

Primary Completion Date

November 1, 2029

Study Completion Date

November 1, 2034

Conditions
Non Small Cell Lung Cancer
Interventions
BIOLOGICAL

CXCR5 modified EGFR Chimeric Antigen Receptor Autologous T cells

The first dose group: 0.5 × 10\^6/kg CAR positive T cells; The second dose group: 1.58 × 10\^6/ kg CAR positive T cells; The third dose group: 5 × 10\^6/kg CAR positive T cells. The above dose allows a 20 % error; For subjects with body weight greater than 60 kg, the number of cells can only be calculated according to 60 kg of body weight.

Trial Locations (1)

510260

RECRUITING

Second Affiliated Hospital of Guangzhou Medical University, Guangzhou

All Listed Sponsors
lead

Second Affiliated Hospital of Guangzhou Medical University

OTHER